Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill help breast cancer that outsmarts two antibody drugs?

NCT ID NCT07810634

Disease control Sponsor: Beijing 302 Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are reviewing medical records to see how well pyrotinib works and how safe it is in people with HER2-positive advanced breast cancer whose disease worsened after treatment with trastuzumab and pertuzumab. The study includes about 200 patients in China who received pyrotinib after those two antibody drugs. The main goal is to measure how long patients live without their cancer getting worse, and researchers also track how many tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pyrotinib, a daily pill that blocks HER2 signals in cancer cells
What this could lead to
If pyrotinib helps this group, it could offer a treatment option for HER2-positive advanced breast cancer that has grown after dual antibody therapy.
What could go wrong
This is a small retrospective review of past records, so it cannot prove cause and effect. Results may not apply to all patients, and pyrotinib can cause side effects such as diarrhea and skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with HER2-positive advanced breast cancer who had previously been treated with either trastuzumab or pertuzumab, and who subsequently received pyrotinib-based therapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Diagnosis of unresectable locally advanced or metastatic breast cancer 2. Confirmed HER2-positive status, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with positive in situ hybridization (ISH) results 3. Prior systemic treatment of trastuzumab and pertuzumab 4. Adequate baseline cardiac, bone marrow, renal, hepatic, and blood coagulation functions 5. Life expectancy \> 3 months 6. ECOG ≤3 Exclusion Criteria: * 1\. Incomplete clinical case data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • The Fifth Medical Center of the PLA General Hospital

    Beijing, Beijing Municipality, 100071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.